Kawarazaki Hiroo, Shibagaki Yugo, Fukumoto Seiji, Kido Ryo, Ando Katsuyuki, Nakajima Ichiro, Fuchinoue Shohei, Fujita Toshiro, Fukagawa Masafumi, Teraoka Satoshi
Department of Nephrology and Endocrinology, University of Tokyo Department of Surgery, Kidney Center, Tokyo, Japan.
Ther Apher Dial. 2011 Oct;15(5):481-7. doi: 10.1111/j.1744-9987.2011.00932.x. Epub 2011 May 25.
Mineral and bone disorders (MBD), including hypercalcemia and hypophosphatemia, are common complications after renal transplantation; however, the natural course of these disorders has not been well documented, and the pathogenesis of persistent post-transplant MBD still remains elusive. This study was carried out to show the natural history of mineral metabolism in recipients after living-donor kidney transplantation and also to clarify post-transplant risk factors of persistent hypercalcemia and/or hypophosphatemia at 12months after transplantation. Living-donor kidney transplant recipients (N=34) at Tokyo Women's Medical University were prospectively and consecutively recruited. Parameters of MBD, including intact parathyroid hormone and full-length fibroblast growth factor23, were followed. Serum calcium levels increased until the fourth week post-transplantation, after which it reached a plateau; and serum phosphate decreased substantially at one week post-kidney transplantation, but recovered to the reference level at two months. Fibroblast growth factor23 gradually decreased to comparable levels for renal function, while hyperparathyroidism persisted for 12months after transplantation. Multivariate linear regression analysis revealed that intact parathyroid hormone was the best correlating factor with both hypercalcemia and persistent hypophosphatemia at 12months. This study suggests the need for testing of other interventions used for treatment of hyperparathyroidism which may help to offer better management of MBD after kidney transplantation.
矿物质与骨代谢紊乱(MBD),包括高钙血症和低磷血症,是肾移植术后常见的并发症;然而,这些紊乱的自然病程尚未得到充分记录,移植后持续性MBD的发病机制仍不清楚。本研究旨在揭示活体供肾移植受者矿物质代谢的自然史,并阐明移植后12个月持续性高钙血症和/或低磷血症的危险因素。东京医科大学的活体供肾移植受者(N = 34)被前瞻性地连续招募。对包括完整甲状旁腺激素和全长成纤维细胞生长因子23在内的MBD参数进行跟踪。血清钙水平在移植后第四周前升高,之后达到平台期;血清磷在肾移植后一周大幅下降,但在两个月时恢复到参考水平。成纤维细胞生长因子23逐渐降至与肾功能相当的水平,而甲状旁腺功能亢进在移植后持续12个月。多变量线性回归分析显示,完整甲状旁腺激素是与移植后12个月高钙血症和持续性低磷血症相关性最好的因素。本研究表明需要对用于治疗甲状旁腺功能亢进的其他干预措施进行测试,这可能有助于更好地管理肾移植后的MBD。